Free Trial
NASDAQ:XOMA

XOMA Q4 2024 Earnings Report

XOMA logo
$24.85 -0.26 (-1.04%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$24.84 -0.01 (-0.02%)
As of 05/23/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.17
One Year Ago EPS
N/A

XOMA Revenue Results

Actual Revenue
$8.70 million
Expected Revenue
$8.75 million
Beat/Miss
Missed by -$47.00 thousand
YoY Revenue Growth
N/A

XOMA Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 17, 2025
Conference Call Time
10:30AM ET

Upcoming Earnings

XOMA's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled at 7:45 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

XOMA Earnings Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
XOMA Royalty: Q1 Earnings Snapshot
See More XOMA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA and other key companies, straight to your email.

About XOMA

XOMA (NASDAQ:XOMA) operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

View XOMA Profile

More Earnings Resources from MarketBeat